Amundi Has $21.09 Million Position in Astera Labs, Inc. $ALAB

Amundi trimmed its stake in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 25.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 378,760 shares of the company's stock after selling 130,752 shares during the quarter. Amundi owned approximately 0.23% of Astera Labs worth $21,089,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ALAB. Adage Capital Partners GP L.L.C. raised its stake in shares of Astera Labs by 802.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 463,932 shares of the company's stock valued at $27,683,000 after purchasing an additional 412,500 shares in the last quarter. Atreides Management LP raised its stake in shares of Astera Labs by 153.3% during the first quarter. Atreides Management LP now owns 4,652,264 shares of the company's stock valued at $277,601,000 after purchasing an additional 2,815,614 shares in the last quarter. PDT Partners LLC raised its stake in shares of Astera Labs by 112.3% during the first quarter. PDT Partners LLC now owns 53,157 shares of the company's stock valued at $3,172,000 after purchasing an additional 28,121 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Astera Labs by 167.3% during the first quarter. Royal Bank of Canada now owns 152,453 shares of the company's stock valued at $9,097,000 after purchasing an additional 95,409 shares in the last quarter. Finally, Graham Capital Management L.P. raised its stake in shares of Astera Labs by 151.8% during the first quarter. Graham Capital Management L.P. now owns 50,652 shares of the company's stock valued at $3,022,000 after purchasing an additional 30,537 shares in the last quarter. 60.47% of the stock is currently owned by institutional investors.

Insider Transactions at Astera Labs

In other Astera Labs news, CFO Michael Truett Tate sold 100,000 shares of the company's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $171.38, for a total value of $17,138,000.00. Following the transaction, the chief financial officer directly owned 518,996 shares of the company's stock, valued at $88,945,534.48. This represents a 16.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jitendra Mohan sold 152,517 shares of the stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $170.33, for a total value of $25,978,220.61. Following the completion of the transaction, the chief executive officer owned 450,001 shares in the company, valued at $76,648,670.33. This represents a 25.31% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,832,489 shares of company stock worth $264,172,396. 12.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. CICC Research started coverage on shares of Astera Labs in a research note on Friday, August 29th. They set an "outperform" rating and a $190.00 price objective on the stock. Jefferies Financial Group upped their price target on shares of Astera Labs from $95.00 to $130.00 and gave the company a "buy" rating in a report on Tuesday, July 22nd. Stifel Nicolaus set a $145.00 price target on shares of Astera Labs and gave the company a "buy" rating in a report on Monday, August 4th. William Blair initiated coverage on shares of Astera Labs in a research note on Thursday, May 22nd. They set an "outperform" rating for the company. Finally, Needham & Company LLC raised their target price on shares of Astera Labs from $100.00 to $170.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Astera Labs presently has a consensus rating of "Moderate Buy" and a consensus target price of $142.00.

Astera Labs Trading Down 1.5%

NASDAQ:ALAB traded down $3.40 on Friday, hitting $229.50. 3,692,811 shares of the company's stock traded hands, compared to its average volume of 4,689,180. Astera Labs, Inc. has a 1 year low of $41.47 and a 1 year high of $237.82. The firm has a 50-day moving average price of $155.12 and a 200-day moving average price of $103.68. The company has a market cap of $38.15 billion, a PE ratio of 409.82, a price-to-earnings-growth ratio of 5.91 and a beta of 1.48.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.11. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The company had revenue of $191.93 million for the quarter, compared to analysts' expectations of $172.46 million. During the same quarter in the previous year, the business posted $0.13 EPS. The business's revenue for the quarter was up 149.5% on a year-over-year basis. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. On average, research analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.